IL243752D0 - Multispecific antibodies, compositions comprising same and uses thereof - Google Patents

Multispecific antibodies, compositions comprising same and uses thereof

Info

Publication number
IL243752D0
IL243752D0 IL243752A IL24375216A IL243752D0 IL 243752 D0 IL243752 D0 IL 243752D0 IL 243752 A IL243752 A IL 243752A IL 24375216 A IL24375216 A IL 24375216A IL 243752 D0 IL243752 D0 IL 243752D0
Authority
IL
Israel
Prior art keywords
compositions
uses
same
multispecific antibodies
multispecific
Prior art date
Application number
IL243752A
Other languages
Hebrew (he)
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201361858402P priority Critical
Priority to PCT/US2014/048289 priority patent/WO2015013671A1/en
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Publication of IL243752D0 publication Critical patent/IL243752D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
IL243752A 2013-07-25 2016-01-24 Multispecific antibodies, compositions comprising same and uses thereof IL243752D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201361858402P true 2013-07-25 2013-07-25
PCT/US2014/048289 WO2015013671A1 (en) 2013-07-25 2014-07-25 Multispecific antibodies, multispecific activatable antibodies and methods of using the same

Publications (1)

Publication Number Publication Date
IL243752D0 true IL243752D0 (en) 2016-04-21

Family

ID=51299065

Family Applications (1)

Application Number Title Priority Date Filing Date
IL243752A IL243752D0 (en) 2013-07-25 2016-01-24 Multispecific antibodies, compositions comprising same and uses thereof

Country Status (12)

Country Link
US (1) US20150079088A1 (en)
EP (2) EP3024851B1 (en)
JP (1) JP6693872B2 (en)
KR (1) KR20160035065A (en)
CN (1) CN105722859A (en)
AU (2) AU2014292924B2 (en)
CA (1) CA2918795A1 (en)
DK (1) DK3024851T3 (en)
ES (1) ES2683268T3 (en)
IL (1) IL243752D0 (en)
RU (1) RU2016106115A3 (en)
WO (1) WO2015013671A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2014022540A1 (en) * 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
SG10201710727UA (en) 2013-05-28 2018-02-27 Dcb Usa Llc Antibody locker for the inactivation of protein drug
CN104342453A (en) * 2013-08-06 2015-02-11 深圳先进技术研究院 Minicircle DNA recombinant parent plasmid containing genetically engineered antibody gene expression cassette, minicircle DNA containing the expression cassette and application thereof
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
US9737623B2 (en) 2013-12-11 2017-08-22 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
SG11201604990PA (en) 2013-12-17 2016-07-28 Genentech Inc Anti-cd3 antibodies and methods of use
DK3148581T3 (en) * 2014-05-30 2020-01-13 Henlix Biotech Co Ltd Anti-epidermal growth factor receptor (egfr) antibodies
AU2015292374A1 (en) * 2014-07-25 2017-03-16 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
US9975951B2 (en) * 2015-05-20 2018-05-22 Immunwork Inc. Peptide core-based multi-arm linkers and their applications
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
CN108289952A (en) * 2015-11-19 2018-07-17 雷维托普有限公司 Functional antibody fragment complementation for two component systems for redirecting killing to non-wanted cell
US10533157B1 (en) 2015-12-03 2020-01-14 Nantbio, Inc. Recombinant NK cells expressing co-stimulatory molecules
BR112018013912A2 (en) * 2016-01-08 2018-12-18 Abgenomics Int Inc tetravalent anti-psgl-1 antibodies and uses thereof
AU2017237376A1 (en) * 2016-03-22 2018-08-02 F. Hoffmann-La Roche Ag Protease-activated T cell bispecific molecules
WO2017201493A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single chain variable fragment cd3 binding proteins
EP3474901A1 (en) 2016-06-27 2019-05-01 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
CN106632681B (en) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 Anti- EGFR and AntiCD3 McAb bispecific antibody and its application
JP2020510653A (en) * 2017-02-27 2020-04-09 ドラゴンフライ セラピューティクス, インコーポレイテッド Multispecific binding proteins targeting CAIX, ANO1, mesothelin, TROP2, CEA or claudin-18.2.
CN110770255A (en) 2017-04-11 2020-02-07 印希彼有限公司 Multispecific polypeptide constructs with restricted CD3 binding and methods of use thereof
US10543271B2 (en) 2017-05-12 2020-01-28 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2018217947A1 (en) * 2017-05-23 2018-11-29 Dragonfly Therapeutics, Inc. A protein binding nkg2d, cd16 and a tumor-associated antigen
US20190055321A1 (en) 2017-08-16 2019-02-21 Bristol-Myers Squibb Company Prodruggable antibodies, prodrugs thereof, and methods of use and making
AU2018347607A1 (en) 2017-10-14 2020-03-26 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
WO2019118411A2 (en) * 2017-12-11 2019-06-20 Triphase Accelerator U.S. Corporation Anti-cd22 antibody-maytansine conjugates, combinations, and methods of use thereof
WO2019183218A1 (en) 2018-03-20 2019-09-26 Cytomx Therapeutics, Inc. Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects
WO2019213444A1 (en) 2018-05-02 2019-11-07 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
WO2019212356A1 (en) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B .V. Tetrazines for high click conjugation yield in vivo and high click release yield
WO2019236567A2 (en) * 2018-06-04 2019-12-12 Trustees Of Tufts College Tumor microenvironment-activated drug-binder conjugated, and uses related thereto
WO2019241216A1 (en) * 2018-06-14 2019-12-19 Bioatla, Llc Multi-specific antibody constructs
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
WO2020028401A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Pharmaceutical formulations of masked antibodies
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
WO2020076992A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. 5t4 single domain antibodies and therapeutic compositions thereof
WO2020076977A2 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
WO2020076970A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1517921E (en) * 2002-06-28 2006-09-29 Domantis Ltd Differently specified ligands with semi-life in the increased serum
CN101466404A (en) * 2006-06-14 2009-06-24 埃姆克隆系统股份有限公司 Lyophilized formulations of anti-EGFR antibodies
WO2009018386A1 (en) * 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
JP6035009B2 (en) * 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Activable binding polypeptides and methods for identification and use thereof
AU2009299794B2 (en) * 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
WO2010042904A2 (en) * 2008-10-10 2010-04-15 Trubion Pharmaceuticals, Inc. Tcr complex immunotherapeutics
US8895702B2 (en) * 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
CN102482347B (en) * 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 Modified antibody compositions, and methods of making and using thereof
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US9120853B2 (en) * 2012-04-27 2015-09-01 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
US9856314B2 (en) * 2012-06-22 2018-01-02 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and methods of using the same
KR20150037857A (en) * 2012-06-22 2015-04-08 싸이톰스 테라퓨틱스, 인크. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
US9487590B2 (en) * 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
US10261083B2 (en) * 2013-01-04 2019-04-16 Cytomx Therapeutics, Inc. Compositions and methods for detecting protease activity in biological systems
CN105658240A (en) * 2013-06-04 2016-06-08 西托姆克斯治疗公司 Compositions and methods for conjugating activatable antibodies
KR20160104612A (en) * 2013-07-26 2016-09-05 업데이트 파마 인코포레이트 Compositions to improve the therapeutic benefit of bisantrene
US9540440B2 (en) * 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
EP3099319A2 (en) * 2014-01-31 2016-12-07 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
EP3172235A2 (en) * 2014-07-25 2017-05-31 Cytomx Therapeutics Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
CN108026170A (en) * 2015-05-04 2018-05-11 西托姆克斯治疗公司 Anti- CD71 antibody, can activate anti-CD71 antibody and its application method

Also Published As

Publication number Publication date
RU2016106115A3 (en) 2018-07-24
WO2015013671A1 (en) 2015-01-29
JP6693872B2 (en) 2020-05-13
DK3024851T3 (en) 2018-08-06
JP2016525551A (en) 2016-08-25
US20150079088A1 (en) 2015-03-19
CN105722859A (en) 2016-06-29
AU2014292924B2 (en) 2019-11-21
CA2918795A1 (en) 2015-01-29
AU2014292924A1 (en) 2016-02-11
EP3024851A1 (en) 2016-06-01
EP3406633A1 (en) 2018-11-28
KR20160035065A (en) 2016-03-30
ES2683268T3 (en) 2018-09-25
EP3024851B1 (en) 2018-05-09
AU2020200981A1 (en) 2020-02-27
RU2016106115A (en) 2017-08-30

Similar Documents

Publication Publication Date Title
IL267758D0 (en) Seed-origin endophyte populations, compositions, and methods of use
HRP20200102T1 (en) Anti-pdl1 antibody formulations
HK1219976A1 (en) Compositions and methods for immunotherapy
IL261743D0 (en) Anti-il-33 antibodies and uses thereof
IL263843D0 (en) Compositions and methods
IL269528D0 (en) Anti-fcrh5 antibodies
HK1218837A1 (en) Compositions and methods
HK1218560A1 (en) Compositions and methods
IL238958D0 (en) Glutamase inhibitors, compositions comprising same and uses thereof
HK1220387A1 (en) Compositions and methods for immunotherapy
HK1214969A1 (en) Anti-pdgfr-beta antibodies and uses thereof -pdgfr-
SG11201507478VA (en) Heteroaryl compounds and uses thereof
HK1203317A1 (en) Edible composition, preparation method and use thereof
IL243974D0 (en) Anti-prlr antibodies and uses thereof
IL238959D0 (en) Glutamase inhibitors, compositions comprising same and uses thereof
IL236348D0 (en) Anti-jagged antibodies, compositions comprising the same and uses thereof
IL240195A (en) Pyridone amide compounds, compositions comprising same and uses thereof
EP2961779A4 (en) Polyethylene processes and compositions thereof
HK1218930A1 (en) Novel multispecific constructs
HK1225715A1 (en) Aza-pyridone compounds and uses thereof
IL238192D0 (en) Antibodies recognizing alpha-synnuclein, compositions comprising same and uses thereof
EP2968304A4 (en) 4-phenylpiperidines, their preparation and use
IL234014A (en) Cycloalkane derivatives, compositions comprising same and uses thereof
EP2968357A4 (en) S-imino-s-oxo iminothiazine compounds as bace inhibitors, compositions, and their use
GB2520795B (en) Compositions and methods